Irwin Gold Sells 29,693 Shares of Houlihan Lokey Inc (NYSE:HLI) Stock

Share on StockTwits

Houlihan Lokey Inc (NYSE:HLI) Chairman Irwin Gold sold 29,693 shares of the stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $48.42, for a total transaction of $1,437,735.06. Following the transaction, the chairman now owns 29,693 shares in the company, valued at approximately $1,437,735.06. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Irwin Gold also recently made the following trade(s):

  • On Thursday, March 19th, Irwin Gold sold 15,000 shares of Houlihan Lokey stock. The stock was sold at an average price of $49.50, for a total transaction of $742,500.00.
  • On Monday, December 30th, Irwin Gold sold 10,000 shares of Houlihan Lokey stock. The stock was sold at an average price of $49.11, for a total transaction of $491,100.00.

Shares of Houlihan Lokey stock opened at $47.49 on Friday. The company has a 50 day moving average of $52.52 and a 200-day moving average of $49.09. Houlihan Lokey Inc has a 1-year low of $41.80 and a 1-year high of $59.36. The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.16. The company has a market cap of $3.10 billion, a PE ratio of 18.34 and a beta of 0.88.

Houlihan Lokey (NYSE:HLI) last issued its quarterly earnings results on Monday, February 3rd. The financial services provider reported $0.88 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.11. The company had revenue of $333.52 million during the quarter, compared to the consensus estimate of $296.36 million. Houlihan Lokey had a net margin of 14.82% and a return on equity of 22.49%. The firm’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.77 EPS. Research analysts forecast that Houlihan Lokey Inc will post 3.09 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 16th. Investors of record on Thursday, March 5th were paid a $0.31 dividend. This represents a $1.24 annualized dividend and a yield of 2.61%. The ex-dividend date was Wednesday, March 4th. Houlihan Lokey’s payout ratio is 43.21%.

HLI has been the topic of a number of analyst reports. ValuEngine upgraded shares of Houlihan Lokey from a “sell” rating to a “hold” rating in a research report on Tuesday, January 21st. Keefe, Bruyette & Woods lowered shares of Houlihan Lokey from an “outperform” rating to a “market perform” rating and increased their target price for the stock from $52.00 to $53.00 in a research report on Sunday, January 26th. UBS Group cut their price target on shares of Houlihan Lokey from $59.00 to $55.00 and set a “buy” rating for the company in a report on Wednesday. Zacks Investment Research raised shares of Houlihan Lokey from a “hold” rating to a “buy” rating and set a $63.00 price target for the company in a report on Thursday, February 6th. Finally, Buckingham Research upped their price target on shares of Houlihan Lokey from $51.00 to $57.00 and gave the stock a “buy” rating in a report on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $53.66.

Large investors have recently modified their holdings of the stock. Assetmark Inc. lifted its stake in Houlihan Lokey by 35.2% in the 4th quarter. Assetmark Inc. now owns 710 shares of the financial services provider’s stock valued at $35,000 after purchasing an additional 185 shares during the last quarter. First Bank & Trust lifted its stake in Houlihan Lokey by 297.7% in the 4th quarter. First Bank & Trust now owns 851 shares of the financial services provider’s stock valued at $42,000 after purchasing an additional 637 shares during the last quarter. Huntington National Bank bought a new position in Houlihan Lokey in the 4th quarter valued at approximately $49,000. CFM Wealth Partners LLC bought a new position in Houlihan Lokey in the 4th quarter valued at approximately $90,000. Finally, Sowell Financial Services LLC lifted its stake in Houlihan Lokey by 15,250.0% in the 4th quarter. Sowell Financial Services LLC now owns 1,842 shares of the financial services provider’s stock valued at $90,000 after purchasing an additional 1,830 shares during the last quarter. 67.48% of the stock is owned by institutional investors and hedge funds.

About Houlihan Lokey

Houlihan Lokey, Inc, an investment banking company, provides merger and acquisition (M&A), financing, financial restructuring, and financial advisory services worldwide. It operates in three segments: Corporate Finance, Financial Restructuring, and Financial Advisory Services. The Corporate Finance segment offers general financial advisory services; and advises public and private institutions on buy-side and sell-side transactions, leveraged loans, private mezzanine debt, high-yield debt, initial public offerings, follow-ons, convertibles, equity private placements, private equity, and liability management transactions, as well as financial sponsors on various transactions.

See Also: History of the Euro STOXX 50 Index

Insider Buying and Selling by Quarter for Houlihan Lokey (NYSE:HLI)

Receive News & Ratings for Houlihan Lokey Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Houlihan Lokey and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Financial Survey: Heico  vs. United Technologies
Financial Survey: Heico vs. United Technologies
Alexander’s  vs. The Competition Head to Head Review
Alexander’s vs. The Competition Head to Head Review
Mcdonald’s  & One Group Hospitality  Critical Comparison
Mcdonald’s & One Group Hospitality Critical Comparison
Reviewing Afya  and Its Competitors
Reviewing Afya and Its Competitors
Head to Head Survey: Allogene Therapeutics  & Allena Pharmaceuticals
Head to Head Survey: Allogene Therapeutics & Allena Pharmaceuticals
XPEL  versus PEN  Financial Analysis
XPEL versus PEN Financial Analysis


 
© 2006-2020 Zolmax.